A Five-Gene Model Predicts Clinical Outcome in ER+/PR+, Early-Stage Breast Cancers Treated with Adjuvant Tamoxifen

被引：13

作者：

Kerr II D.A. ^{[1
]}

Wittliff J.L. ^{[1
]}

机构：

[1] Department of Biochemistry and Molecular Biology, Brown Cancer Center and Institute for Molecular Diversity and Drug Design, University of Louisville, Louisville

来源：

Hormones and Cancer | 2011年 / 2卷 / 5期

关键词：

Breast cancer; Disease-free survival; Estrogen receptor; Gene expression; Overall survival; Progesterone receptor; Tamoxifen;

D O I：

10.1007/s12672-011-0080-8

中图分类号：

学科分类号：

摘要：

Primary breast carcinomas expressing both estrogen and progesterone receptors are most likely to respond to tamoxifen therapy, especially in patients with early-stage lesions. However, certain patients exhibit clinicopathologic features suggesting good prognosis relapse within 10 years, justifying a search for biomarkers identifying patients at risk for recurrence. Nine candidate genes associated with estrogen signaling were selected from microarray studies and combined with those for conventional biomarkers (ESR1, PGR, ERBB2). Expression of this 12-gene subset was analyzed by RT-qPCR in frozen tissue specimens from 60 early-stage, estrogen receptor (ER)+/progestin receptor (PR)+ breast cancers from patients treated with adjuvant tamoxifen. A multivariate model was created by Cox regression using a training data set and applied to an independent validation set. A five-gene model was developed from the training set (n=36) that exhibited significant correlations with both relapse-free and overall survival. Applying this model to Kaplan-Meier regression, patients were separated into low-risk (100% relapse-free at 150 months) and high-risk (60% relapse-free at 150 months) groups (P = 0.03). When this model was applied to the validation set (n=24), similar risk stratification was achieved for both relapse-free and overall survival (P = 0.01 and 0.04, respectively). We developed a five-gene model composed of PgR, BCL2, ERBB4 JM-a, RERG, and CD34 that identified early-stage, ER+/PR+ breast cancers in patients treated with tamoxifen that relapsed, although they exhibited clinicopathologic features suggesting good prognosis. Within this multivariate model, increased expression of PgR, ERBB4 JM-a, RERG, and CD34 was associated with increased survival, while increased expression of BCL2 was associated with decreased survival. © 2011 Springer Science+Business Media, LLC.

引用

页码：261 / 271

页数：10

共 45 条

[1]

Cleator S.J., Ahamed E., Coombes R.C., Palmieri C., A 2009 update on the treatment of patients with hormone receptor-positive breast cancer, Clin. Breast Cancer, 9, SUPPL. 1, pp. 6-17, (2009)

[2]

Fleisher M., Dnistrian A.M., Sturgeon C.M., Wittliff J.L., Practice guidelines and recommendations for use of tumor markers in the clinic, Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications, pp. 33-63, (2002)

[3]

Sturgeon C.M., Duffy M.J., Stenman U.H., Et al., National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers, Clin Chem, 54, pp. 11-79, (2008)

[4]

Wittliff J.L., Pasic R., Bland K.I., Steroid and peptide hormone receptors: methods, quality control, and clinical use, The Breast: Comprehensive Management of Benign and Malignant Diseases, pp. 458-498, (1998)

[5]

Harris L., Fritsche H., Mennel R., Et al., American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer, J Clin Oncol, 25, pp. 5287-5312, (2007)

[6]

Bezwoda W.R., Esser J.D., Dansey R., Kessel I., Lange M., The value of estrogen and progesterone receptor determinations in advanced breast cancer. Estrogen receptor level but not progesterone receptor level correlates with response to tamoxifen, Cancer, 68, pp. 867-872, (1991)

[7]

Dowsett M., Houghton J., Iden C., Et al., Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status, Ann Oncol, 17, pp. 818-826, (2006)

[8]

Payne S.J., Bowen R.L., Jones J.L., Wells C.A., Predictive markers in breast cancer-the present, Histopathology, 52, pp. 82-90, (2008)

[9]

Wittliff J.L., Steroid-hormone receptors in breast cancer, Cancer, 53, pp. 630-643, (1984)

[10]

Grann V.R., Troxel A.B., Zojwalla N.J., Jacobson J.S., Hershman D., Neugut A.I., Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma, Cancer, 103, pp. 2241-2251, (2005)

← 1 2 3 4 5 →